US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...
Syndax confirms FDA approval of Revuforj for acute leukemia
Pharmaceuticals announced that the U.S. FDA has approved Revuforj as the first and only menin inhibitor for the treatment of ...
FDA approves Syndax’s Revuforj for acute leukemia
The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute ...
GlobalData on MSN13h
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
FiercePharma17h
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
ophthalmologyadvisor8h
Photobiomodulation Treatment Receives FDA Authorization for Dry AMD Therapy
The Valeda ® Light Delivery System (LumiThera, Inc.) is the first ever FDA-authorized treatment for vision loss in dry AMD, the manufacturer reported. The technology was evaluated in the LIGHTSITE III ...